A deep dive into US drug discovery

<p style="font-weight: 400;">This is the latest episode of the free DDW narrated podcast, “What lies in the future for genomics and big data?", which covers two articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “<a href= "https://www.ddw-online.com/us-biotech-focus-on-positive-growth-and-innovation-25515-202208/" target="_blank" rel="noopener">US biotech: Focus on positive growth and innovation</a>”, and “<a href= "https://www.ddw-online.com/sitting-down-with-calidi-biotherapeutics-18017-202207/" target="_blank" rel="noopener">Sitting down with Calidi Biotherapeutics</a>”.</p> <p>In the first article, DDW’s Lu Rahman takes a snapshot of the US biotech market and how its successes are having a positive effect on its UK counterpart.</p> <p>In the second article, Dr Boris Minev, President of Medical and Scientific Affairs at Calidi Biotherapeutics speaks to DDW’s Reece Armstrong about the company’s approach to treating cancer.</p>